LON:AVO Advanced Oncotherapy (AVO) Share Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free AVO Stock Alerts GBX 1.75 -0.18 (-9.09%) (As of 08/30/2023) Add Compare Share Share Today's Range 1.75▼ 1.7550-Day Range 1.75▼ 1.7552-Week Range 1.75▼ 25.75Volume200,000 shsAverage Volume1.27 million shsMarket Capitalization£9.49 millionP/E RatioN/ADividend Yield5.49%Price TargetN/A Stock AnalysisStock AnalysisInsider TradesStock AnalysisInsider Trades Get Advanced Oncotherapy alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Advanced Oncotherapy Stock (LON:AVO)Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.Read More AVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVO Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comAdvanced Oncotherapy (LON:AVO) Stock Price Crosses Below Two Hundred Day Moving Average of $1.79January 23, 2024 | lse.co.ukAdvanced Oncotherapy Share ChatMarch 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.December 9, 2023 | morningstar.comAdvanced Oncotherapy PLC AVOJune 12, 2023 | finance.yahoo.comFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired StockJune 12, 2023 | finance.yahoo.comFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired Stock \January 27, 2023 | finanznachrichten.deHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to dateJanuary 3, 2023 | finance.yahoo.comIndependent Non-Executive Director Michael Bradfield Just Bought 6.4% More Shares In Advanced Oncotherapy plc (LON:AVO)March 29, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.December 13, 2022 | marketwatch.comAdvanced Oncotherapy Raises GBP1.5 Mln Via High-Premium Share SubscriptionOctober 27, 2022 | proactiveinvestors.comProactive news headlines: Deepverge, Greatland Gold, Seeing Machines, and moreSeptember 29, 2022 | uk.finance.yahoo.comHardman & Co Research on Advanced Oncotherapy: Major milestone achievedSeptember 8, 2022 | finance.yahoo.comAdvanced Oncotherapy plc (LON:AVO) has caught the attention of institutional investors who hold a sizeable 39% stakeAugust 1, 2022 | finance.yahoo.comIs Now An Opportune Moment To Examine Advanced Oncotherapy plc (LON:AVO)?July 2, 2022 | finance.yahoo.comCalculating The Intrinsic Value Of Advanced Oncotherapy plc (LON:AVO)March 31, 2022 | proactiveinvestors.comAdvanced Oncotherapy's technology can slash costs of proton therapy cancer treatment says CEOMarch 26, 2022 | proactiveinvestors.com.auProactive weekly mining highlights: Horizonte, Atlantic Lithium, East Star and moreMarch 25, 2022 | proactiveinvestors.comAdvanced Oncotherapy raises £2mln at a premiumMarch 1, 2022 | proactiveinvestors.comFTSE 100 in the red as fighting in Ukraine is intensifying with RussiaMarch 1, 2022 | proactiveinvestors.comAdvanced Oncotherapy hails significant progress with regulatory submission as it updates on its timelineFebruary 25, 2022 | finance.yahoo.comAdvanced Oncotherapy plc (AVO.L)December 13, 2021 | proactiveinvestors.comAdvanced Oncotherapy says it is making good progress, but confirms previously-flagged delayNovember 15, 2021 | markets.businessinsider.comHardman & Co Research: Advanced Oncotherapy (AVO): On the home straightOctober 2, 2021 | finance.yahoo.comIs Advanced Oncotherapy plc (LON:AVO) Popular Amongst Insiders?September 2, 2021 | proactiveinvestors.comAdvanced Oncotherapy - Result of GM, TVR and clarification re warrantsAugust 12, 2021 | markets.businessinsider.comAdvanced Oncotherapy : Result of AGMAugust 12, 2021 | finanznachrichten.deHardman & Co Research: Advanced Oncotherapy (AVO) Funded to completionSee More Headlines Receive AVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Advanced Oncotherapy and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/29/2020Today3/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolLON:AVO CUSIPN/A CIKN/A Webwww.advancedoncotherapy.com Phone+44-20-36178728FaxN/AEmployees174Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-32,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.34% Return on Assets-11.73% Debt Debt-to-Equity Ratio98.71 Current Ratio1.26 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.05 per share Price / Cash Flow33.50 Book ValueGBX 14 per share Price / Book0.13Miscellaneous Outstanding Shares542,570,000Free FloatN/AMarket Cap£9.49 million OptionableNot Optionable Beta0.09 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Michael Jeffrey Sinclair (Age 82)Executive Chairman Comp: $434.42kMr. Nicolas Serandour (Age 49)CEO & Executive Director Comp: $502.96kProf. Stephen Myers OBE (Age 78)Executive Director Comp: $397.72kMr. Ed LeeCOO & President of EuropeMr. Graham PugheSenior Vice-President of AccountingMs. Berengere Pons-ChabordSenior Vice-President of Corporate FinanceMore ExecutivesKey CompetitorsPolarean ImagingLON:POLXMyHealthCheckedLON:MHCRUA Life SciencesLON:RUASurgical Innovations GroupLON:SUNInspiration Healthcare GroupLON:IHCView All Competitors AVO Stock Analysis - Frequently Asked Questions How have AVO shares performed in 2024? Advanced Oncotherapy's stock was trading at GBX 1.75 at the beginning of the year. Since then, AVO shares have increased by 0.0% and is now trading at GBX 1.75. View the best growth stocks for 2024 here. How were Advanced Oncotherapy's earnings last quarter? Advanced Oncotherapy plc (LON:AVO) issued its earnings results on Monday, June, 29th. The company reported ($9.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($8.90) by $0.93. What other stocks do shareholders of Advanced Oncotherapy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Oxford Biomedica (OXB), BMR Group (BMR), GW Pharmaceuticals (GWPH), Lancashire (LRE), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW). How do I buy shares of Advanced Oncotherapy? Shares of AVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:AVO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Advanced Oncotherapy plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.